Saint-Gobain // Universal Registration Document 2021

Financial and accounting information Statutory Auditors’ report on the financial statements

These matters were addressed in the context of our audit of the financial statements as a whole and in forming our opinion thereon, and we do not provide a separate opinion on specific items of the financial statements.

Measurement of investments in subsidiaries and affiliates and related loans and advances Description of risk At December 31, 2021, the carrying amount of the Company’s investments in subsidiaries and affiliates and related loans and advances stood at €26,603 million, representing 78% of the net assets of the company. Investments in subsidiaries and affiliates are initially stated at cost and are impaired based on their value in use, corresponding to the amount the Company would be prepared to pay for the investment if it were to acquire it. A decline in the performance of certain subsidiaries or affiliates or risks relating to the international locations of those companies could lead to impairment losses. We deemed the measurement of the value in use of these investments, which is performed each year by Management using the multi-criteria approach described in Note 1 to the financial statements, to be a key audit matter in light of the potential materiality of any impairment and the high degree of estimation and judgment required from Management to assess impairment losses, especially in the context of Covid-19’s crisis. Management’s judgment is based in part on assumptions relating, on the one hand, to the multiples applicable to the valuation of the investments and, on the other, to future changes in the cash flows relating to the investments, as well as to the calculation of the appropriate discount rate applied to future cash flows. The impairment tests performed by Management have led to book a reversal of impairment amounting to €345 million and impairment losses amounting to €1 million for the year ended December 31, 2021. How our audit addressed this risk We examined the impairment test procedure applied by the Company’s financial management team, especially the consideration of the impacts of the Covid’s 19 health crisis, verified the consistency of the method used and tested the effectiveness of the controls implemented by Management to ensure the quality and reliability of the procedure. We carried out an independent analysis of certain key assumptions used by Management to perform the tests, pertaining, as appropriate, to the multiple deemed applicable to the valuation of the investments or to the discount rate and average perpetual growth rate used to project future cash flows, referring both to external market data and analyses of comparable companies. For each investment selected for our tests of detail, we corroborated the calculation parameters applied in Management’s multi-criteria approach with the accounting and budget data available for that investment. Where projected future cash flows were used, we analyzed the consistency of the projections with past performance and our knowledge of the Company’s business, supported by interviews with managers from the various businesses, we also analyzed qualitative and quantitative parameters related to the depth and the potential length of the Covid-19’s crisis and, in so far as they were available, external data relating to markets or competitors. We paid particularly close attention to the calculation of the normalized amount of the terminal cash flows projected to perpetuity. We verified the disclosures provided in the notes to the financial statements concerning the valuation of investments in subsidiaries and affiliates and related loans and advances to ensure their appropriateness. 3. Specific verifications We have also performed, in accordance with professional standards applicable in France, the specific verifications required by laws and regulations. Information given in the management report and in the other documents with respect to the financial position and the financial statements provided to the Shareholders We have no matters to report as to the fair presentation and the consistency with the financial statements of the information given in the management report of the Board of Directors and in the other documents with respect to the financial position and the financial statements provided to the Shareholders. We attest the fair presentation and the consistency with the financial statements of the information relating to the payment deadlines mentioned in Article D.441-4 of the French Commercial Code (code de commerce). Report on corporate governance We attest that the Board of Directors’ report on corporate governance sets out the information required by Articles L.225-37-4, L.22-10-10 and L.22-10-9 of the French Commercial Code (code de commerce). Concerning the information given in accordance with the requirements of Article L.22-10-9 of the French Commercial Code (code de commerce) relating to remunerations and benefits received by the directors and any other commitments made in their favour, we have verified its consistency with the financial statements, or with the underlying information used to prepare these financial statements and, where applicable, with the information obtained by your company from controlling and controlled companies. Based on these procedures, we attest the accuracy and fair presentation of this information. With respect to the information relating to items that your company considered likely to have an impact in the event of a takeover bid or exchange offer, provided pursuant to Article L.22 of the French Commercial Code (code de commerce), we have agreed this information to the source documents communicated to us. Based on these procedures, we have no observations to make on this information.

8

SAINT-GOBAIN UNIVERSAL REGISTRATION DOCUMENT 2021 365